A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder

Stewart, S. Evelyn; Jenike, Eric; Hezel, Dianne M.; Stack, Denise Egan; Dodman, Nicholas H.; Shuster, Louis; Jenike, Michael A.

doi:10.1097/jcp.0b013e3181c856de

Cited by 139 publications

(88 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other potential but as yet unproven approaches in the management of patients with treatment-resistant obsessive-compulsive disorder include monotherapy with once-weekly morphine [I (PCT)] (Koran et al, 2005); and the glutamate-modulating compounds riluzole [III] (Coric et al, 2005;Pittenger et al, 2008), memantine [III] (Stewart et al, 2010), and glycine [I (PCT) (Greenberg et al, 2009). Some patients with treatment-refractory obsessive-compulsive disorder may benefit from deep brain stimulation and other neurosurgical approaches [IV] (Blomstedt et al, 2012;De Koning et al, 2011;Greenberg et al, 2010 …”

Section: Further Management After Nonresponse To Initial Treatmentmentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

show abstract

Section: Further Management After Nonresponse To Initial Treatmentmentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The role of NMDAR and glutamate-modulating agents such as D-cycloserine, riluzole, ketamine, and memantine is now being explored in resistant depression, mood disorders, and obsessive compulsive disorders [19,20,21]. Although there are reports [4] of depression with MDR-TB treatment, which may be the effect of coprescribed drugs in regime; but it cannot be attributed specifically to cycloserine, in view of its mechanism of action of NMDAR antagonism and partial agonism at the NMDAR-associated glycine.…”

Section: Discussionmentioning

confidence: 99%

Cycloserine Induced-Psychosis in a 22-Year Old Male Pharmacy Student: A Case Report

Kennedy¹

2016

AJPN

View full text Add to dashboard Cite

This is case of cycloserine induced-psychosis in a 22-year old male patient on treatment for multi-drugs resistant tuberculosis (MDRTB) at the Aluu MDRTB centre of UPTH. Tuberculosis is a chronic respiratory infection caused by mycobacterium tuberculosis. Cycloserine is a Category IV antimycobacterial agent used for the treatment of resistant tuberculosis. The overall clinical scenerio forms this case report. The aim of this report was to highlight a case of cycloserine induced-psychosis in a 22-year old male patient on treatment for drug resistant tuberculosis at the Aluu MDRTB centre of UPTH and to further point to the fact that it is reversible. The case report of the patient was retrieved and reviewed together with relevant literatures. A 22-year old male patient who was diagnosed of tuberculosis in December, 2013 andrediagnosed as multidrug resistant tuberculosis about 6 months ago. He was admitted as a referral into the MDRTBcentre at Aluu5 months following the later and commenced on a course of Category IV anti TB regimen including cycloserine at a dose of 75 Omg dly. There was no history of use of psychoactive substances and no family history of mental illnesses. His body weight as at the time of the report was 47 kg. Routine and other investigations including full blood count with differencials, electrolyte, urea and creatinine and urinalysis, thyroid function test done were all within normal ranges. Retroviral screening test was seronegative. Within 1week of commencing the antituberculosis regimen, patient began to manifest a range of psychotic features unusual abnormal behaviours characterized by irrational talks, seeing of strange images unseen by others in clear conscious. After detailed evaluation and with high index of suspicion, a diagnosis of cycloserine-induced psychosis was entertained. The psychiatrist recommended that the cycloerinebe withheld and patient was commenced on low dose atypical antipsychotic agent. Within 48hours, symptoms began to resolve and within 72 hours there was marked improvement particularly in the psychotic symptoms. A good number of medications like cycloserine have been known to induce psychosis. Clinicians should always apply caution particularly in dosage and assess patients fitness for these group of medications. This will help to prevent precipitation of psychiatric adverse symptoms and guarantee the patient optimal care.

show abstract

“…Its use in OCD has been demonstrated in open-label trials [80,81]. A recent RCT found significant improvement in the memantine group compared with controls [82].…”

Section: Memantinementioning

confidence: 99%

Augmentation strategies in obsessive–compulsive disorder

Arumugham

Reddy

2013

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder

Abstract: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. Future randomized double-blind placebo-controlled trials are warranted.

Cited by 139 publications

References 47 publications

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Cycloserine Induced-Psychosis in a 22-Year Old Male Pharmacy Student: A Case Report

Augmentation strategies in obsessive–compulsive disorder

Contact Info

Product

Resources

About